Terms: = Skin cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
819 results:
1. Primary prophylaxis with mtor inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V; Abdelhamid K; Noto A; Latifyan S; Martina F; Daoudlarian D; De Micheli R; Pruijm M; Peters S; Hullin R; Gaide O; Pantaleo G; Obeid M
Nat Commun; 2024 Apr; 15(1):3664. PubMed ID: 38693123
[TBL] [Abstract] [Full Text] [Related]
2. Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression.
Lee YH; Yoon AR; Yun CO; Chung KC
J Biol Chem; 2024 Apr; 300(4):107206. PubMed ID: 38519031
[TBL] [Abstract] [Full Text] [Related]
3. Exploring the Interplay of RUNX2 and CXCR4 in Melanoma Progression.
Dalle Carbonare L; Minoia A; Vareschi A; Piritore FC; Zouari S; Gandini A; Meneghel M; Elia R; Lorenzi P; Antoniazzi F; Pessoa J; Zipeto D; Romanelli MG; Guardavaccaro D; Valenti MT
Cells; 2024 Feb; 13(5):. PubMed ID: 38474372
[TBL] [Abstract] [Full Text] [Related]
4. Persistent β-Hexachlorocyclohexane Exposure Impacts Cellular Metabolism with a Specific Signature in Normal Human Melanocytes.
Papaccio F; Caputo S; Iorio A; De Simone P; Ottaviani M; Del Brocco A; Frascione P; Bellei B
Cells; 2024 Feb; 13(5):. PubMed ID: 38474338
[TBL] [Abstract] [Full Text] [Related]
5. Novel MED15::ATF1 fusion in a pediatric melanoma with spitzoid features and aggressive presentation.
Furtado LV; Cardenas M; Santiago T; Ruiz RE; Shi Z; Pappo A; Kacar M
Genes Chromosomes Cancer; 2024 Mar; 63(3):e23230. PubMed ID: 38459940
[TBL] [Abstract] [Full Text] [Related]
6. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations.
Liu XL; Run-Hua Z; Pan JX; Li ZJ; Yu L; Li YL
Pigment Cell Melanoma Res; 2024 May; 37(3):411-425. PubMed ID: 38411373
[TBL] [Abstract] [Full Text] [Related]
7. Conjunctival leiomyosarcoma: A clinico-pathological study with in deep molecular characterization.
Santoro A; Angelico G; Mulè A; Minucci A; Giannuzzi F; Sammarco MG; Pagliara MM; Blasi MA
Pathol Res Pract; 2024 Mar; 255():155182. PubMed ID: 38335782
[TBL] [Abstract] [Full Text] [Related]
8. CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance.
Kharouf N; Flanagan TW; Alamodi AA; Al Hmada Y; Hassan SY; Shalaby H; Santourlidis S; Hassan SL; Haikel Y; Megahed M; Brodell RT; Hassan M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334632
[TBL] [Abstract] [Full Text] [Related]
9. Mycophenolate mofetil inhibits Merkel cell carcinoma growth.
Garman KA; Thoreson N; Strong J; Hallaert P; Gelb T; Shen M; Hall MD; Brownell I
Br J Dermatol; 2024 Mar; 190(4):593-595. PubMed ID: 38266271
[TBL] [Abstract] [Full Text] [Related]
10. Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides.
Bordeaux ZA; Reddy SV; Choi J; Braun G; McKeel J; Lu W; Yossef SM; Ma EZ; West CE; Kwatra SG; Kwatra MM
Sci Rep; 2024 Jan; 14(1):1955. PubMed ID: 38263212
[TBL] [Abstract] [Full Text] [Related]
11. Nickel-doped vanadium pentoxide (Ni@V
Nivetha S; Srivalli T; Sathya PM; Mohan H; Karthi N; Muralidharan K; Ramalingam V
Colloids Surf B Biointerfaces; 2024 Feb; 234():113763. PubMed ID: 38262106
[TBL] [Abstract] [Full Text] [Related]
12. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
[TBL] [Abstract] [Full Text] [Related]
13. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mtor-mitochondrial ROS signaling.
Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
[TBL] [Abstract] [Full Text] [Related]
14. ATF5 promotes malignant T cell survival through the PI3K/AKT/mtor pathway in cutaneous T cell lymphoma.
Cao M; Lai P; Liu X; Liu F; Qin Y; Tu P; Wang Y
Front Immunol; 2023; 14():1282996. PubMed ID: 38223508
[TBL] [Abstract] [Full Text] [Related]
15. Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Immunohistochemistry Can Be a Useful Ancillary Tool to Identify Perivascular Epithelioid Cell Tumor.
Wangsiricharoen S; Ingram DR; Morey RR; Wani K; Lazar AJ; Wang WL
Mod Pathol; 2024 Mar; 37(3):100426. PubMed ID: 38219952
[TBL] [Abstract] [Full Text] [Related]
16. Loureirin A Promotes Cell Differentiation and Suppresses Migration and Invasion of Melanoma Cells via WNT and AKT/mtor Signaling Pathways.
Xia ZY; Liu L; Kuok CF; Wang XL; Shi D; Ma Q; Cheng XY; Wang GL; Li MJ; Zheng QS; Liu XN; Li DF; Li BH
Biol Pharm Bull; 2024 Feb; 47(2):486-498. PubMed ID: 38199251
[TBL] [Abstract] [Full Text] [Related]
17. S6K1 deficiency in tumor stroma impairs lung metastasis of melanoma in mice.
Kim DE; Roh HS; Kim GH; Bhang DH; Um SH; Singh R; Baek KH
Biochem Biophys Res Commun; 2024 Feb; 696():149469. PubMed ID: 38194806
[TBL] [Abstract] [Full Text] [Related]
18. Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mtor pathway in mucosal melanoma fitness.
Monti M; Benerini Gatta L; Bugatti M; Pezzali I; Picinoli S; Manfredi M; Lavazza A; Vanella VV; De Giorgis V; Zanatta L; Missale F; Lonardi S; Zanetti B; Bozzoni G; Cadei M; Abate A; Vergani B; Balzarini P; Battocchio S; Facco C; Turri-Zanoni M; Castelnuovo P; Nicolai P; Fonsatti E; Leone BE; Marengo E; Sigala S; Ronca R; Perego M; Lombardi D; Vermi W
J Transl Med; 2024 Jan; 22(1):35. PubMed ID: 38191367
[TBL] [Abstract] [Full Text] [Related]
19. Prevalence and spectrum of infectious and inflammatory dermatologic conditions occurring in pediatric heart transplant patients on a predominantly mtor-based immune suppressive regimen: A retrospective chart review.
Rydberg A; Ameduri R; Brown T; Johnson JN; Todd A; Tollefson MM; Anderson K
Pediatr Transplant; 2024 Feb; 28(1):e14664. PubMed ID: 38149373
[TBL] [Abstract] [Full Text] [Related]
20. β-endorphin suppresses ultraviolet B irradiation-induced epidermal barrier damage by regulating inflammation-dependent mtorC1 signaling.
Kim HS; Kim HJ; Hong YD; Son ED; Cho SY
Sci Rep; 2023 Dec; 13(1):22357. PubMed ID: 38102220
[TBL] [Abstract] [Full Text] [Related]
[Next]
